Global Nuclear Medicine Size, Share and Trend Analysis Report 2022: 24.4 Billion Market by 2030 - Upcoming Approval of Multiple Radiopharmaceutical Therapies -

Global Nuclear Medicine Size, Share and Trend Analysis Report 2022: 24.4 Billion Market by 2030 – Upcoming Approval of Multiple Radiopharmaceutical Therapies –

DUBLIN, May 25, 2022— (BUSINESS WIRE) – Report “Market size, share and trends in the analysis of the nuclear medicine market by product (diagnostics (SPECT, PET)), therapy (alpha emitters, beta emitters, brachytherapy), by application, by region and segment The Forecast forecast, 2022-2030 “has been added. offer.

The size of the global nuclear medicine market is expected to reach $ 24.4 billion by 2030 and expand by CAGR 13.0% between 2022 and 2030.

The growing prevalence of chronic diseases such as cancer and thyroid is expected to lead to market growth. The forthcoming approval of more radiopharmaceuticals during the forecast period will be the main driving force of the market. For example, in March 2022, Novartis AG received approval for Pluvicto (Lu 177) for the treatment of adult patients with prostate cancer.

According to the Pan American Health Organization (PAHO), in 2022, it is estimated that approximately 20 million new cases of cancer and approximately 10 million deaths from the disease will be diagnosed worldwide. Factors such as lifestyle changes, unhealthy diets and lower oral hygiene awareness in low- and middle-income countries are the most common causes of cancer prevalence.

The growing introduction of nuclear medicine products in the diagnosis and approval of new generators, which will help increase the supply of radionuclides, is expected to lead to growth. For example, in November 2021, EZAG received approval from the Brazilian Health Regulatory Agency (ANVISA) for GalliaPharm in Brazil.

It is a gallium-68 generator used to extract the positron-emitting gallium isotope from a decomposing germanium-68 source to produce G68 dopate. This is the first and only gallium generator approved for pharmaceutical use in Brazil. The approval of these products contributes to market growth in emerging markets.

In light of the COVID-19 pandemic, the market was slightly affected. The Reactor-Based Medical Isotope Survey was conducted by the International Atomic Energy Agency (IAEA) during the second quarter of 2020 to assess supply chain continuity during the COVID-19 crisis.

It was revealed that the major manufacturers continued to produce in accordance with IAEA safety standards because their operations were identified as essential by the respective governments.

The most important news about the nuclear medicine market

  • by product type, the SPECT segment had the largest share of the diagnostics market due to its low price, high accuracy and wide range of applications.

  • The PET segment is expected to grow lucratively over the forecast period through the approval and launch of new products, such as PYLARIFY PET prostate cancer imaging agent.

  • according to the application, the oncology segment dominated the market in 2021 with a share of 42.06%.

  • North America dominated the global market in 2021 thanks to increased awareness of current therapies, favorable reimbursement policies, and better affordability for patients.

  • The Asia-Pacific region is expected to grow significantly in the future due to the growing prevalence of chronic diseases, growing geriatric populations and the approval of new products during the forecast period.

Industrial outlook

Analysis of market variables

  • Growing incidence of cancer and cardiovascular disease

  • Growing applications of radiopharmaceuticals / nuclear medicine

  • Growing demand for accurate diagnostic methods

Market restriction analysis

  • Strict regulations regarding production, storage and use

  • High costs associated with diagnostics and therapeutic procedures

SWOT analysis; by factor (political and legal, economic and technological)

Porter’s analysis of the five forces

Value chain analysis

Production process and trends

  • Production of molybdenum-99 (Spect radioisotopes)

  • Follow radioisotope trends

  • Trends in radioisotopes of domestic animals

  • Production of PET Radioisotopes

  • Trends in therapeutic radioisotopes

  • Production process and trends

Radiopharmaceutical Market – Impact on Covid-19

Pipeline analysis

The mentioned companies

  • Eckert & Ziegler

  • Mallinckrodt

  • Curium Pharma

  • General Electric

  • Jubilant Life Sciences Ltd.

  • Bracco Imaging SPA

  • Nordion (Canada), Inc.

  • Ire-Ire Elit-Be Institute

  • Australian Organization for Nuclear Science and Technology (Ansto)

  • Ntp Radioisotopes Soc Ltd.

  • Eczacibasi-Monrol

  • Lantheus Medical Imaging, Inc.

For more information on this report, visit

View source at

Laura Wood, Chief Press Officer

For EST office hours, call 1-917-300-0470
For US / CAN, call toll-free 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

Source link

Leave a Comment

Your email address will not be published.